Mifegyne (Mifepristone)

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a 200 mg tablet for oral use. It is employed for medical termination of early pregnancy and, in some regions, for off‑label management of Cushing's syndrome. GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mifegyne is a progesterone receptor antagonist used in the following clinical situations:

Medical termination of early pregnancy: induces abortion in early gestation when combined with a prostaglandin analogue. Cushing's syndrome (off‑label): reduces cortisol production by antagonising glucocorticoid receptors.

Mifegyne may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Vomiting - Abdominal cramping or pain - Vaginal bleeding or spotting - Diarrhea - Headache

Serious or Rare Side Effects: - Heavy or prolonged uterine bleeding - Severe infection (sepsis) - Allergic reaction including rash or anaphylaxis - Liver injury or hepatitis - Uterine rupture - Hyperkalemia

Before prescribing Mifegyne, clinicians should consider several safety measures.

Confirm gestational age: ensure pregnancy is within the approved gestational limit. Verify negative pregnancy test: rule out ectopic pregnancy. Assess contraindications: chronic adrenal failure, anticoagulant therapy, severe anemia. Administer under medical supervision: monitor vital signs and bleeding. Avoid concomitant anticoagulants: increase risk of hemorrhage. Store at below 25°C: keep in the original pack, protect from moisture.

Mifegyne can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Rifampin: induces hepatic metabolism, reducing efficacy. - Carbamazepine: accelerates clearance, lowering drug levels. - St. John's wort: induces CYP enzymes, diminishing therapeutic effect.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of gastrointestinal bleeding. - Anticoagulants (e.g., warfarin): heightened bleeding potential.